Recursion Pharmaceuticals is trading 6.15% down in pre-market at $3.51 on October 15, 2026, as broader market pressure weighs on growth shares. - September inflation exceeded forecasts, reviving higher-for-longer rate concerns. - Nasdaq futures were down 1.13% in the supplied market context. - No clear company-specific announcement tied to the move surfaced; recent coverage discussed earlier analyst estimate cuts and sentiment, not a fresh catalyst.